LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Modulation of the AMPK/Sirt1 axis during neuronal infection by herpes simplex virus type 1.

    Martin, Carolina / Leyton, Luis / Arancibia, Yennyfer / Cuevas, Alexei / Zambrano, Angara / Concha, Margarita I / Otth, Carola

    Journal of Alzheimer's disease : JAD

    2014  Volume 42, Issue 1, Page(s) 301–312

    Abstract: Currently, it is unclear whether a neuron that undergoes viral reactivation and produces infectious particles survives and resumes latency or is killed, which is intriguing even if still unanswered. Previous reports have shown that herpes simplex virus ... ...

    Abstract Currently, it is unclear whether a neuron that undergoes viral reactivation and produces infectious particles survives and resumes latency or is killed, which is intriguing even if still unanswered. Previous reports have shown that herpes simplex virus type 1 (HSV-1) inhibits apoptosis during early infection, but is pro-apoptotic during productive infection. Taking in consideration that the stress sensors AMPK and Sirt1 are involved in neuronal survival and neuroprotection, we hypothesized that HSV-1 could activate the AMPK/Sirt1 axis as a strategy to establish latency through inhibition of apoptosis and restoration of the energy status. These effects could be accomplished through deacetylation of pro-apoptotic protein p53 and regulation of the master regulator of mitochondrial biogenesis and function PGC-1α and its target gene TFAM. Accordingly, we evaluated the AMPK/Sirt1 axis and its targets p53, PGC-1α, and acetyl CoA carboxylase in mice neuronal cultures infected with HSV-1 by western blot, RT-qPCR, and immunofluorescence analyses. Herein, we show that HSV-1 differentially modulates the AMPK/Sirt1 axis during the course of infection. In fact, during early infection (2 hpi) activated AMPK (p-AMPK) was down-regulated, but thereafter recovered gradually. In contrast, the levels of acetylated-p53 increased during the first hours post infection, but afterwards were reduced in parallel with the activation of Sirt1. However, acetylated-p53 peaked again at 18 hpi during productive infection, suggesting an activation of apoptosis. Strikingly, acetylated-p53, Sirt1, and p-AMPK apparently translocate from the nucleus to the cytoplasm after 4 hpi, where they accumulate in discrete foci in the perinuclear region. These results suggest that HSV-1 modulates the AMPK/Sirt1 axis differentially during the course of infection interfering with pro-apoptotic signaling and regulating mitochondrial biogenesis.
    MeSH term(s) AMP-Activated Protein Kinases/metabolism ; Animals ; Blotting, Western ; Cell Nucleus/metabolism ; Cells, Cultured ; Cytoplasm/metabolism ; Disease Progression ; Herpes Simplex/metabolism ; Herpesvirus 1, Human ; Mice ; Microscopy, Fluorescence ; Neurons/immunology ; Real-Time Polymerase Chain Reaction ; Signal Transduction ; Sirtuin 1/metabolism ; Tumor Suppressor Protein p53/metabolism
    Chemical Substances Tumor Suppressor Protein p53 ; AMP-Activated Protein Kinases (EC 2.7.11.31) ; Sirt1 protein, mouse (EC 3.5.1.-) ; Sirtuin 1 (EC 3.5.1.-)
    Language English
    Publishing date 2014
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-140237
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.

    Valenzuela Nieto, Guillermo / Jara, Ronald / Watterson, Daniel / Modhiran, Naphak / Amarilla, Alberto A / Himelreichs, Johanna / Khromykh, Alexander A / Salinas-Rebolledo, Constanza / Pinto, Teresa / Cheuquemilla, Yorka / Margolles, Yago / López González Del Rey, Natalia / Miranda-Chacon, Zaray / Cuevas, Alexei / Berking, Anne / Deride, Camila / González-Moraga, Sebastián / Mancilla, Héctor / Maturana, Daniel /
    Langer, Andreas / Toledo, Juan Pablo / Müller, Ananda / Uberti, Benjamín / Krall, Paola / Ehrenfeld, Pamela / Blesa, Javier / Chana-Cuevas, Pedro / Rehren, German / Schwefel, David / Fernandez, Luis Ángel / Rojas-Fernandez, Alejandro

    Scientific reports

    2021  Volume 11, Issue 1, Page(s) 3318

    Abstract: Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to reduce the burden placed on health systems, the situation remains critical. Effective diagnosis, treatment, and prophylactic measures are urgently required to meet ...

    Abstract Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to reduce the burden placed on health systems, the situation remains critical. Effective diagnosis, treatment, and prophylactic measures are urgently required to meet global demand: recombinant antibodies fulfill these requirements and have marked clinical potential. Here, we describe the fast-tracked development of an alpaca Nanobody specific for the receptor-binding-domain (RBD) of the SARS-CoV-2 Spike protein with potential therapeutic applicability. We present a rapid method for nanobody isolation that includes an optimized immunization regimen coupled with VHH library E. coli surface display, which allows single-step selection of Nanobodies using a simple density gradient centrifugation of the bacterial library. The selected single and monomeric Nanobody, W25, binds to the SARS-CoV-2 S RBD with sub-nanomolar affinity and efficiently competes with ACE-2 receptor binding. Furthermore, W25 potently neutralizes SARS-CoV-2 wild type and the D614G variant with IC50 values in the nanomolar range, demonstrating its potential as antiviral agent.
    MeSH term(s) Angiotensin-Converting Enzyme 2/immunology ; Animals ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Antibody Affinity/genetics ; COVID-19/immunology ; COVID-19/virology ; Camelids, New World/immunology ; Escherichia coli/genetics ; Escherichia coli/metabolism ; Green Fluorescent Proteins/genetics ; HeLa Cells ; Humans ; Immunization ; Male ; Neutralization Tests ; Peptide Library ; Protein Binding/genetics ; SARS-CoV-2/chemistry ; SARS-CoV-2/immunology ; SARS-CoV-2/isolation & purification ; Single-Domain Antibodies/immunology ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/immunology ; Transfection
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; Peptide Library ; Single-Domain Antibodies ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; Green Fluorescent Proteins (147336-22-9) ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
    Language English
    Publishing date 2021-02-08
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-021-82833-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity Nanobody

    Nieto, Guillermo Valenzuela / Jara, Ronald / Watterson, Daniel / Modhiran, Naphak / Amarilla, Alberto A / Himelreichs, Johanna / Khromykh, Alexander A. / Salinas, Constanza / Pinto, Teresa / Cheuquemilla, Yorka / Margolles, Yago / González del Rey, Natalia López / Miranda-Chacon, Zaray / Cuevas, Alexei / Berking, Anne / Deride, Camila / González-Moraga, Sebastián / Mancilla, Héctor / Maturana, Daniel /
    Langer, Andreas / Toledo, Juan Pablo / Müller, Ananda / Uberti, Benjamín / Krall, Paola / Ehrenfeld, Pamela / Blesa, Javier / Chana-Cuevas, Pedro / Rehren, German / Schwefel, David / Fernandez, Luis Ángel / Rojas-Fernandez, Alejandro

    bioRxiv

    Abstract: Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to reduce the burden placed on health systems, the situation remains critical. Effective diagnosis, treatment, and prophylactic measures are urgently required to meet ...

    Abstract Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to reduce the burden placed on health systems, the situation remains critical. Effective diagnosis, treatment, and prophylactic measures are urgently required to meet global demand: recombinant antibodies fulfill these requirements and have marked clinical potential. Here, we describe the fast-tracked development of an alpaca Nanobody specific for the receptor-binding-domain (RBD) of the SARS-CoV-2 Spike protein with therapeutic potential applicability. We present a rapid method for nanobody isolation that includes an optimized immunization regimen coupled with VHH library E. coli surface display, which allows single-step selection of high-affinity nanobodies using a simple density gradient centrifugation of the bacterial library. The selected single and monomeric Nanobody, W25, binds to the SARS-CoV-2 S RBD with sub-nanomolar affinity and efficiently competes with ACE-2 receptor binding. Furthermore, W25 potently neutralizes SARS-CoV-2 wild type and the D614G variant with IC50 values in the nanomolar range, demonstrating its potential as antiviral agent.
    Keywords covid19
    Publisher BioRxiv; WHO
    Document type Article ; Online
    DOI 10.1101/2020.06.09.137935
    Database COVID19

    Kategorien

  4. Article ; Online: Fast isolation of sub-nanomolar affinity alpaca nanobody against the Spike RBD of SARS-CoV-2 by combining bacterial display and a simple single-step density gradient selection

    Valenzuela Nieto, Guillermo E. / Jara, Ronald / Himelreichs, Johanna / Salinas, Constanza / Pinto, Teresa / Cheuquemilla, Yorka / Margolles, Yago / López González del Rey, Natalia / Chacon, Zaray Miranda / Cuevas, Alexei / Berking, Anne / Deride, Camila / Gonzalez-Moraga, Sebastian / Mancilla, Hector / Maturana, Daniel / Langer, Andreas / Toledo, Juan Pablo / Müller, Ananda / Uberti, Benjamin /
    Krall, Paola / Ehrenfeld, Pamela / Blesa, Javier / Chana-Cuevas, Pedro / Rehren, German / Fernández, Luis Ángel / Rojas-Fernandez, Alejandro

    2020  

    Abstract: Despite the worldwide efforts to avoid disease progression of COVID-19 into a severe acute respiratory syndrome and avoid its severe impact on health systems; the situation remains critical. Effective diagnosis, treatment, and prophylactic measures are ... ...

    Abstract Despite the worldwide efforts to avoid disease progression of COVID-19 into a severe acute respiratory syndrome and avoid its severe impact on health systems; the situation remains critical. Effective diagnosis, treatment, and prophylactic measures are required to meet the worldwide demand: recombinant antibodies such as alpaca Nanobodies fulfill these requirements. Here, we develop a fast track for nanobody isolation against the receptor-binding-domain (RBD) SARS-CoV-2 Spike protein following an optimized immunization, efficient construction of the VHH library for E. coli surface display, and single-step selection of high-affinity nanobodies using a simple density gradient centrifugation of the bacterial library. Following this procedure, we isolate and characterize an alpaca Nanobody against Spike RBD of SARS-CoV-2 in the sub-nanomolar range.

    No
    Keywords covid19
    Language English
    Publishing date 2020-06-10
    Publisher BioRxiv
    Publishing country es
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top